Our Approach to TreatmentThe physician-scientists at Houston Methodist DeBakey Heart & Vascular Center and Houston Methodist Research Institute collaborate and screen cancer patients to better understand why some develop chemotherapy-induced cardiomyopathy. We are working to establish screening protocols to help doctors worldwide reach earlier diagnoses and treatments before our cancer survivors develop heart failure caused by chemotherapeutic agents.
Cardiologist Barry Trachtenberg, MD, is conducting a pilot program to determine whether some cancer patients are genetically inclined to develop chemotherapy-induced cardiomyopathy. He also is investigating innovative biomarkers to predict cardiac damage onset. Our cardiologists and oncologists ensure patients safely receive chemotherapy and closely monitor them for cardiac damage.
Heart muscle damage caused by some chemotherapy agents.
Chemotherapy agents, including some prescribed for:
- Shortness of breath
- Chest pains or palpitations
- Edema, or fluid collection in body cavities or tissues
- Echocardiogram using strain technique, for myocardial function assessment
- Heart-specific biomarkers
- Cardiac CT scan
- Cardiac MRI
- Cardiac bisopsy, but rarely
Our physicians at Houston Methodist specialize in managing chemotherapy-induced cardiomyopathy at the following convenient locations.